

Product datasheet for **TP723471**

VEGFA (NM_001033756) Human Recombinant Protein

Product data:

Product Type:	Recombinant Proteins
Description:	Purified recombinant protein of Human vascular endothelial growth factor A (VEGFA), transcript variant 7.
Species:	Human
Expression Host:	E. coli
Expression cDNA Clone or AA Sequence:	APMAEGGGQN HHEVVKFMDV YQRSYCHPIE TLVDIFQEYP DEIEYIFKPS CVPLMRCGGC CNDEGLECVP TEESNITMQI MRIKPHQGQH IGEMSFLQHN KCECRPKKDR ARQENCDKPR R
Tag:	Tag Free
Predicted MW:	28.4 kDa
Concentration:	lot specific
Purity:	>95% as determined by SDS-PAGE and Coomassie blue staining
Buffer:	Lyophilized from a 0.2 μ M filtered solution of 20mM phosphate buffer, 100mM NaCl, pH 7.2
Bioactivity:	Determined by the dose-dependent stimulation of the proliferation of human umbilical vein endothelial cells (HUVEC) using a concentration range of 0.2-0.4 ng/ml.
Endotoxin:	Endotoxin level is < 0.1 ng/ μ g of protein (< 1 EU/ μ g)
Storage:	Store at -80°C.
Stability:	Stable for at least 6 months from date of receipt under proper storage and handling conditions.
RefSeq:	NP_001028928
Locus ID:	7422
UniProt ID:	P15692
RefSeq Size:	3476
Cytogenetics:	6p21.1
RefSeq ORF:	1113
Synonyms:	MVCD1; VEGF; VPF



[View online »](#)

Summary:

This gene is a member of the PDGF/VEGF growth factor family. It encodes a heparin-binding protein, which exists as a disulfide-linked homodimer. This growth factor induces proliferation and migration of vascular endothelial cells, and is essential for both physiological and pathological angiogenesis. Disruption of this gene in mice resulted in abnormal embryonic blood vessel formation. This gene is upregulated in many known tumors and its expression is correlated with tumor stage and progression. Elevated levels of this protein are found in patients with POEMS syndrome, also known as Crow-Fukase syndrome. Allelic variants of this gene have been associated with microvascular complications of diabetes 1 (MVCD1) and atherosclerosis. Alternatively spliced transcript variants encoding different isoforms have been described. There is also evidence for alternative translation initiation from upstream non-AUG (CUG) codons resulting in additional isoforms. A recent study showed that a C-terminally extended isoform is produced by use of an alternative in-frame translation termination codon via a stop codon readthrough mechanism, and that this isoform is antiangiogenic. Expression of some isoforms derived from the AUG start codon is regulated by a small upstream open reading frame, which is located within an internal ribosome entry site. The levels of VEGF are increased during infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), thus promoting inflammation by facilitating recruitment of inflammatory cells, and by increasing the level of angiotensin II (Ang II), one of two products of the SARS-CoV-2 binding target, angiotensin-converting enzyme 2 (ACE2). In turn, Ang II facilitates the elevation of VEGF, thus forming a vicious cycle in the release of inflammatory cytokines. [provided by RefSeq, Jun 2020]

Protein Families:

Druggable Genome, Secreted Protein

Protein Pathways:

Bladder cancer, Cytokine-cytokine receptor interaction, Focal adhesion, mTOR signaling pathway, Pancreatic cancer, Pathways in cancer, Renal cell carcinoma, VEGF signaling pathway

Product images: